Tag Archives: TrialNet

Efforts to prevent or delay type 1 diabetes have traditionally focused on the autoimmune attack that destroys insulin-producing beta cells. However, emerging research suggests metabolic stress may also influence how quickly vulnerable people progress to clinical disease. A 2026 TrialNet analysis found that autoantibody-positive people with overweight or obesity who …

For many years, C-peptide testing was viewed as a simple tool to distinguish type 1 diabetes from type 2 diabetes. However, the story has changed. As researchers gain a better understanding of pancreatic beta-cell function, C-peptide testing in diabetes has become much more valuable than a diagnostic aid alone. Today, …

Population-based screening for type 1 diabetes is entering a new era. While autoantibody testing remains the gold standard for identifying individuals at high risk, researchers are increasingly investigating whether type 1 diabetes genetic screening could identify susceptible people even earlier. Advances in genomic science now make it possible to estimate …